Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHOP + RT + Zevalin for High-Risk Localized Aggressive NHL
NCT00070018Phase 2
Key facts
- Status
- Completed
- Start
- Feb 2004
- Primary completion
- Nov 2010
- Countries
- 1
- Sponsor
- SWOG Cancer Research Network
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Drugs
- ibritumomab tiuxetan
- Conditions
- non-Hodgkin lymphoma (NHL)
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in non-Hodgkin lymphoma (NHL), sponsored by SWOG Cancer Research Network. Primary endpoints: Progression-free Survival at 2 years and Toxicity. Started Feb 2004; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
CHOP + RT + Zevalin
CHOP x 3 -> RT -> Zevalin
03
Who it enrols
Patients with stage I, IE, or non-bulky stage II/IIE aggressive CD20+ non-Hodgkin lymphoma with at least one high-risk factor (age >= 60, stage II, Zubrod PS 2, or elevated LDH).
04
Endpoints
Primary
Progression-free Survival
Toxicity
Beyond the preview
Go deeper on NCT00070018.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00070018.